Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| BMRN - Biomarin Pharmaceutical | 12.75% | Reduce −3.3% | 2,139,614 | $77.10 | $165M | −73,336 | −$31M |
| Abiomed | 12.66% | Reduce −4.7% | 494,397 | $331.24 | $164M | −24,636 | −$23M |
| INSM - Insmed | 10.69% | Reduce −2.4% | 5,881,299 | $23.50 | $138M | −144,407 | −$26M |
| UTHR - United Therapeutics | 9.06% | Reduce −5.0% | 653,079 | $179.41 | $117M | −34,127 | −$31M |
| FOLD - Amicus | 7.25% | Reduce −2.1% | 9,903,761 | $9.47 | $94M | −210,282 | −$23M |
| Staar Surgical | 7.02% | Reduce −0.3% | 1,136,968 | $79.91 | $91M | −3,543 | −$13M |
| Revance Therapeutics | 6.66% | Add +1.1% | 4,415,689 | $19.50 | $86M | +46,323 | +$15M |
| BIIB - Biogen | 5.88% | Reduce −6.2% | 360,981 | $210.60 | $76M | −24,019 | −$16M |
| PRTA - Prothena | 4.75% | Reduce −0.2% | 1,681,477 | $36.57 | $61M | −3,805 | −$22M |
| ACAD - Acadia Pharmaceuticals | 4.22% | Reduce −3.7% | 2,251,834 | $24.22 | $55M | −86,043 | −$27K |
| Karyopharm Therapeutics | 3.20% | Add +2.8% | 5,621,533 | $7.37 | $41M | +151,081 | +$6M |
| Sage Therapeutics | 2.18% | Add +9.0% | 851,719 | $33.10 | $28M | +69,989 | −$5M |
| VNDA - Vanda Pharmaceuticals | 2.18% | Reduce −12.1% | 2,491,200 | $11.31 | $28M | −343,044 | −$16M |
| EHTH - Ehealth | 1.59% | Add +2.3% | 1,652,260 | $12.41 | $21M | +36,690 | −$21M |
| ALGN - Align Technology | 1.49% | Reduce −20.0% | 44,305 | $436.00 | $19M | −11,100 | −$17M |
| ALKS - Alkermes | 1.37% | Reduce −10.7% | 673,571 | $26.31 | $18M | −80,629 | +$179K |
| Gossamer Bio | 1.18% | Reduce −0.9% | 1,756,757 | $8.68 | $15M | −16,193 | −$5M |
| Kezar Life Sciences | 0.84% | Hold | 656,200 | $16.62 | $11M | — | — |
| ANAB - Anaptysbio | 0.82% | Reduce −1.3% | 431,024 | $24.74 | $11M | −5,568 | −$5M |
| SNDX - Syndax Pharmaceuticals | 0.82% | Add +2.3% | 612,600 | $17.38 | $11M | +13,700 | −$2M |
| Gritstone Oncology | 0.74% | Reduce −1.1% | 2,330,504 | $4.12 | $10M | −25,778 | −$21M |
| Clovis Oncology | 0.70% | Add +11.9% | 4,473,967 | $2.02 | $9M | +476,141 | −$2M |
| Epizyme | 0.60% | Add +23.5% | 6,774,541 | $1.15 | $8M | +1,289,328 | −$6M |
| TVTX - Travere Therapeutics | 0.33% | Hold | 166,069 | $25.77 | $4M | — | — |
| CYTK - Cytokinetics | 0.32% | Reduce −9.7% | 111,717 | $36.81 | $4M | −11,969 | −$2M |
| Rigel Pharmaceuticals | 0.15% | Hold | 652,395 | $2.99 | $2M | — | — |
| MIRM - Mirum Pharmaceuticals | 0.11% | Hold | 64,700 | $22.02 | $1M | — | — |
| Magenta Therapeutics | 0.10% | Hold | 432,300 | $2.90 | $1M | — | — |
| Alimera Sciences | 0.09% | Hold | 200,919 | $5.60 | $1M | — | — |
| NVAX - Novavax | 0.07% | Hold | 12,500 | $73.68 | $921K | — | — |
| ALDX - Aldeyra Therapeutics | 0.06% | Hold | 160,800 | $4.45 | $715K | — | — |
| Holding | 0.04% | Hold | 27,100 | $20.15 | $546K | — | — |
| Kaleido Biosciences | 0.04% | Reduce −9.2% | 309,692 | $1.65 | $511K | −31,338 | −$304K |
| Marinus Pharmaceuticals | 0.02% | Hold | 31,330 | $9.35 | $293K | — | — |
| URGN - Urogen Pharma | 0.02% | Hold | 24,500 | $8.69 | $213K | — | — |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2